In a report released today, Matt Hewitt from Craig-Hallum assigned a Buy rating to BioLife Solutions (BLFS – Research Report). The company’s shares closed last Friday at $17.50.
Hewitt covers the Healthcare sector, focusing on stocks such as Codexis, Apyx Medical, and Schrodinger. According to TipRanks, Hewitt has an average return of -1.7% and a 45.80% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for BioLife Solutions with a $20.00 average price target.
See today’s best-performing stocks on TipRanks >>
BLFS market cap is currently $788.3M and has a P/E ratio of -7.38.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioLife Solutions (BLFS) Company Description:
BioLife Solutions, Inc. engages in the development, manufacture, and marketing of biopreservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1998 and it is headquartered in Bothell, WA.
Read More on BLFS:
